Symbols / RMTI
RMTI Chart
About
Rockwell Medical, Inc., together with its subsidiaries, develops, manufactures, commercializes, and distributes various hemodialysis products for dialysis providers worldwide. The company offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, centrisol and renasol hemodialysis concentrates, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers. Its hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. In addition, the company offers dialysis concentrates, dialysis kits, and other ancillary products used in the dialysis process. The company was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 36.65M |
| Enterprise Value | 26.44M | Income | -5.93M | Sales | 75.58M |
| Book/sh | 0.94 | Cash/sh | 0.60 | Dividend Yield | — |
| Payout | 0.00% | Employees | 244 | IPO | — |
| P/E | — | Forward P/E | 13.29 | PEG | — |
| P/S | 0.48 | P/B | 0.99 | P/C | — |
| EV/EBITDA | -10.08 | EV/Sales | 0.35 | Quick Ratio | 3.34 |
| Current Ratio | 3.92 | Debt/Eq | 35.45 | LT Debt/Eq | — |
| EPS (ttm) | -0.18 | EPS next Y | 0.07 | EPS Growth | — |
| Revenue Growth | -43.80% | Earnings | 2026-03-26 | ROA | -5.25% |
| ROE | -16.68% | ROIC | — | Gross Margin | 15.15% |
| Oper. Margin | -9.95% | Profit Margin | -7.30% | Shs Outstand | 39.41M |
| Shs Float | 35.24M | Short Float | 1.94% | Short Ratio | 0.47 |
| Short Interest | — | 52W High | 2.10 | 52W Low | 0.78 |
| Beta | 1.69 | Avg Volume | 694.23K | Volume | 297.50K |
| Target Price | $3.75 | Recom | None | Prev Close | $0.94 |
| Price | $0.93 | Change | -1.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$3.75
Mean price target
2. Current target
$0.93
Latest analyst target
3. DCF / Fair value
$-1.08
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.93
Low
$2.50
High
$5.00
Mean
$3.75
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-26 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-11-13 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-03-24 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-12-23 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-11-25 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-11-14 | init | Rodman & Renshaw | — → Buy | $5 |
| 2024-08-12 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-03-25 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2023-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-10-05 | init | Maxim Group | — → Buy | $5 |
| 2023-10-04 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-09-28 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-07-17 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-05-30 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2023-05-02 | reit | HC Wainwright & Co. | — → Buy | $7 |
| 2023-04-04 | reit | HC Wainwright & Co. | — → Buy | $7 |
| 2023-02-13 | reit | HC Wainwright & Co. | — → Buy | $7 |
| 2023-02-08 | main | HC Wainwright & Co. | — → Buy | $7 |
- Is Rockwell Medical (RMTI) Stock Undervalued Right Now? - Yahoo Finance Wed, 28 Jan 2026 08
- Dialysis firm Rockwell Medical is a 'Great Place to Work' — 4 years straight - Stock Titan hu, 12 Feb 2026 08
- Rockwell Medical, Inc.'s (NASDAQ:RMTI) Shares Bounce 32% But Its Business Still Trails The Industry - simplywall.st ue, 03 Feb 2026 08
- $RMTI stock is up 26% today. Here's what we see in our data. - Quiver Quantitative ue, 20 Jan 2026 08
- Despite Fast-paced Momentum, Rockwell Medical (RMTI) Is Still a Bargain Stock - Nasdaq Wed, 28 Jan 2026 08
- Why Fast-paced Mover Rockwell Medical (RMTI) Is a Great Choice for Value Investors - Bitget Mon, 16 Feb 2026 08
- Is Rockwell Medical Stock Built to Withstand More Downside? - Trefis Sat, 20 Dec 2025 08
- Loss Report: Can RMTI deliver alpha - July 2025 Chart Watch & Expert Approved Trade Ideas - baoquankhu1.vn Wed, 25 Feb 2026 10
- Earnings call transcript: Rockwell Medical Q3 2025 sees revenue drop, stock falls - Investing.com Wed, 12 Nov 2025 08
- Rockwell Medical, Inc. (NASDAQ:RMTI) Shares Could Be 34% Below Their Intrinsic Value Estimate - simplywall.st ue, 19 Aug 2025 07
- $RMTI stock is up 15% today. Here's what we see in our data. - Quiver Quantitative Mon, 25 Aug 2025 07
- Dialysis provider extends supply pact with Rockwell Medical to 2026 - Stock Titan Mon, 05 Jan 2026 08
- Is Rockwell Medical (NASDAQ:RMTI) A Risky Investment? - simplywall.st Wed, 17 Dec 2025 08
- Are Investors Undervaluing Rockwell Medical (RMTI) Right Now? - Yahoo Finance Fri, 13 Feb 2026 08
- Rockwell Medical Inc (RMTI) Q3 2025 Earnings Call Highlights: Navigating Challenges and Seizing ... - Yahoo Finance Wed, 12 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 886 | 740 | — | Sale at price 0.84 per share. | NERI JESSE | Chief Financial Officer | — | 2026-01-02 00:00:00 | D |
| 1 | 2868 | 2396 | — | Sale at price 0.84 per share. | HUNTER HEATHER R. | Chief Operating Officer | — | 2026-01-02 00:00:00 | D |
| 2 | 5079 | 4419 | — | Sale at price 0.87 per share. | COOPER JOHN G | Director | — | 2025-11-18 00:00:00 | D |
| 3 | 25000 | — | — | Stock Award(Grant) at price 0.00 per share. | DAWSON JOSEPH H. | Director | — | 2025-11-17 00:00:00 | D |
| 4 | 6926 | 8242 | — | Sale at price 1.19 per share. | STROBECK MARK | Chief Executive Officer | — | 2025-10-01 00:00:00 | D |
| 5 | 886 | 1054 | — | Sale at price 1.19 per share. | NERI JESSE | Chief Financial Officer | — | 2025-10-01 00:00:00 | D |
| 6 | 2868 | 3413 | — | Sale at price 1.19 per share. | CHOLE TIMOTHY | Officer | — | 2025-10-01 00:00:00 | D |
| 7 | 2868 | 3413 | — | Sale at price 1.19 per share. | HUNTER HEATHER R. | Chief Operating Officer | — | 2025-10-01 00:00:00 | D |
| 8 | 6926 | 5679 | — | Sale at price 0.82 per share. | STROBECK MARK | Chief Executive Officer | — | 2025-07-01 00:00:00 | D |
| 9 | 6926 | 5679 | — | Sale at price 0.82 per share. | STROBECK MARK | Chief Executive Officer | — | 2025-07-01 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | 2.88M | -5.01M | -16.17M | -27.80M |
| TotalUnusualItems | 74.00K | 321.00K | 4.00K | |
| TotalUnusualItemsExcludingGoodwill | 74.00K | 321.00K | 4.00K | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -480.00K | -8.44M | -18.68M | -32.67M |
| ReconciledDepreciation | 2.18M | 1.44M | 576.00K | 2.52M |
| ReconciledCostOfRevenue | 84.00M | 74.91M | 68.73M | 64.35M |
| EBITDA | 2.95M | -4.69M | -16.17M | -27.80M |
| EBIT | 774.00K | -6.14M | -16.74M | -30.31M |
| NetInterestIncome | -1.16M | -2.09M | -1.90M | -2.34M |
| InterestExpense | 1.25M | 2.30M | 1.94M | 2.36M |
| InterestIncome | 92.00K | 211.00K | 33.00K | 22.00K |
| NormalizedIncome | -554.00K | -8.76M | -18.68M | -32.67M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -480.00K | -8.44M | -18.68M | -32.67M |
| TotalExpenses | 100.88M | 90.28M | 89.59M | 92.27M |
| TotalOperatingIncomeAsReported | 608.00K | -6.67M | -16.78M | -30.34M |
| DilutedAverageShares | 31.06M | 23.32M | 9.87M | 8.53M |
| BasicAverageShares | 31.06M | 23.32M | 9.87M | 8.53M |
| DilutedEPS | -0.03 | -0.37 | -1.89 | -3.83 |
| BasicEPS | -0.03 | -0.37 | -1.89 | -3.83 |
| DilutedNIAvailtoComStockholders | -782.00K | -8.59M | -18.68M | -32.67M |
| NetIncomeCommonStockholders | -782.00K | -8.59M | -18.68M | -32.67M |
| OtherunderPreferredStockDividend | 302.00K | 150.00K | ||
| NetIncome | -480.00K | -8.44M | -18.68M | -32.67M |
| NetIncomeIncludingNoncontrollingInterests | -480.00K | -8.44M | -18.68M | -32.67M |
| NetIncomeContinuousOperations | -480.00K | -8.44M | -18.68M | -32.67M |
| PretaxIncome | -480.00K | -8.44M | -18.68M | -32.67M |
| OtherIncomeExpense | 74.00K | 321.00K | 4.00K | |
| GainOnSaleOfSecurity | 74.00K | 321.00K | 4.00K | |
| NetNonOperatingInterestIncomeExpense | -1.16M | -2.09M | -1.90M | -2.34M |
| InterestExpenseNonOperating | 1.25M | 2.30M | 1.94M | 2.36M |
| InterestIncomeNonOperating | 92.00K | 211.00K | 33.00K | 22.00K |
| OperatingIncome | 608.00K | -6.67M | -16.78M | -30.34M |
| OperatingExpense | 16.88M | 15.37M | 20.86M | 27.92M |
| ResearchAndDevelopment | 19.00K | 1.11M | 3.12M | 6.83M |
| SellingGeneralAndAdministration | 16.86M | 14.27M | 17.74M | 21.08M |
| SellingAndMarketingExpense | 2.75M | 2.12M | 2.09M | 5.73M |
| GeneralAndAdministrativeExpense | 14.11M | 12.14M | 15.64M | 15.35M |
| OtherGandA | 14.11M | 12.14M | 15.64M | 15.35M |
| GrossProfit | 17.48M | 8.70M | 4.08M | -2.42M |
| CostOfRevenue | 84.00M | 74.91M | 68.73M | 64.35M |
| TotalRevenue | 101.49M | 83.61M | 72.81M | 61.93M |
| OperatingRevenue | 101.49M | 83.61M | 72.81M | 61.93M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 34.06M | 29.13M | 12.16M | 8.54M |
| ShareIssued | 34.06M | 29.13M | 12.16M | 8.54M |
| NetDebt | 7.72M | |||
| TotalDebt | 13.54M | 13.44M | 16.36M | 28.89M |
| TangibleBookValue | 21.46M | 9.61M | 13.19M | 1.61M |
| InvestedCapital | 41.33M | 29.83M | 23.80M | 23.54M |
| WorkingCapital | 22.94M | 12.13M | 17.62M | 14.32M |
| NetTangibleAssets | 21.46M | 9.61M | 13.19M | 1.61M |
| CapitalLeaseObligations | 4.79M | 4.90M | 6.67M | 7.89M |
| CommonStockEquity | 32.59M | 21.29M | 14.11M | 2.54M |
| TotalCapitalization | 41.06M | 29.58M | 21.66M | 15.72M |
| TotalEquityGrossMinorityInterest | 32.59M | 21.29M | 14.11M | 2.54M |
| StockholdersEquity | 32.59M | 21.29M | 14.11M | 2.54M |
| GainsLossesNotAffectingRetainedEarnings | 54.00K | -1.00K | 163.00K | 52.00K |
| OtherEquityAdjustments | 54.00K | -1.00K | 163.00K | 52.00K |
| RetainedEarnings | -397.68M | -397.20M | -388.76M | -370.08M |
| AdditionalPaidInCapital | 430.21M | 418.49M | 402.70M | 372.56M |
| CapitalStock | 3.00K | 3.00K | 1.00K | 1.00K |
| CommonStock | 3.00K | 3.00K | 1.00K | 1.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 26.62M | 30.88M | 32.53M | 46.04M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 12.53M | 14.24M | 14.84M | 25.07M |
| OtherNonCurrentLiabilities | 14.00K | 14.00K | 14.00K | |
| NonCurrentDeferredLiabilities | 1.43M | 2.98M | 2.60M | 5.99M |
| NonCurrentDeferredRevenue | 429.00K | 475.00K | 2.60M | 5.99M |
| LongTermDebtAndCapitalLeaseObligation | 11.10M | 11.26M | 12.22M | 19.07M |
| LongTermCapitalLeaseObligation | 2.63M | 2.96M | 4.67M | 5.89M |
| LongTermDebt | 8.47M | 8.29M | 7.55M | 13.19M |
| CurrentLiabilities | 14.09M | 16.64M | 17.69M | 20.97M |
| CurrentDeferredLiabilities | 2.51M | 2.79M | 1.80M | 2.31M |
| CurrentDeferredRevenue | 143.00K | 289.00K | 1.80M | 2.31M |
| CurrentDebtAndCapitalLeaseObligation | 2.43M | 2.18M | 4.14M | 9.82M |
| CurrentCapitalLeaseObligation | 2.17M | 1.94M | 2.00M | 2.00M |
| CurrentDebt | 268.00K | 244.00K | 2.13M | 7.82M |
| OtherCurrentBorrowings | 1.63M | 7.38M | ||
| CurrentNotesPayable | 268.00K | 244.00K | 503.00K | 437.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.92M | 2.67M | 2.87M | 2.17M |
| PayablesAndAccruedExpenses | 6.22M | 9.00M | 8.88M | 6.66M |
| CurrentAccruedExpenses | 3.35M | 4.48M | 4.83M | 2.92M |
| Payables | 2.87M | 4.52M | 4.05M | 3.74M |
| AccountsPayable | 2.87M | 4.52M | 4.05M | 3.74M |
| TotalAssets | 59.21M | 52.17M | 46.63M | 48.57M |
| TotalNonCurrentAssets | 22.18M | 23.40M | 11.32M | 13.29M |
| OtherNonCurrentAssets | 706.00K | 705.00K | 1.80M | 2.14M |
| GoodwillAndOtherIntangibleAssets | 11.13M | 11.68M | 921.00K | 921.00K |
| OtherIntangibleAssets | 10.21M | 10.76M | ||
| Goodwill | 921.00K | 921.00K | 921.00K | 921.00K |
| NetPPE | 10.34M | 11.02M | 8.61M | 10.22M |
| AccumulatedDepreciation | -10.40M | -8.80M | -7.64M | -7.10M |
| GrossPPE | 20.75M | 19.82M | 16.24M | 17.33M |
| Leases | 1.56M | 1.42M | 1.26M | 1.20M |
| OtherProperties | 5.37M | 5.42M | 7.22M | 8.41M |
| MachineryFurnitureEquipment | 13.82M | 12.98M | 7.77M | 7.71M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 37.03M | 28.77M | 35.31M | 35.29M |
| OtherCurrentAssets | 1.36M | 1.06M | 1.75M | 2.86M |
| PrepaidAssets | 2.86M | |||
| Inventory | 5.78M | 5.87M | 5.81M | 4.08M |
| FinishedGoods | 2.40M | 3.27M | 2.11M | |
| WorkInProcess | 367.00K | 351.00K | 351.00K | |
| RawMaterials | 3.01M | 2.25M | 3.35M | |
| Receivables | 8.29M | 10.90M | 6.26M | 5.91M |
| AccountsReceivable | 8.29M | 10.90M | 6.26M | 5.91M |
| AllowanceForDoubtfulAccountsReceivable | 0.00 | -81.00K | -33.00K | -16.00K |
| GrossAccountsReceivable | 8.29M | 10.98M | 6.29M | 5.93M |
| CashCashEquivalentsAndShortTermInvestments | 21.60M | 10.94M | 21.49M | 22.44M |
| OtherShortTermInvestments | 5.94M | 1.95M | 11.39M | 9.16M |
| CashAndCashEquivalents | 15.66M | 8.98M | 10.10M | 13.28M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 3.19M | -9.70M | -17.21M | -34.06M |
| RepurchaseOfCapitalStock | 0.00 | -6.00K | ||
| RepaymentOfDebt | -1.20M | -3.51M | -13.68M | -2.28M |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 10.18M | 14.86M | 30.02M | 107.00K |
| CapitalExpenditure | -1.01M | -284.00K | -281.00K | -522.00K |
| InterestPaidSupplementalData | 847.00K | 1.21M | 1.47M | 1.83M |
| EndCashPosition | 15.66M | 8.98M | 10.10M | 13.28M |
| BeginningCashPosition | 8.98M | 10.10M | 13.28M | 48.68M |
| EffectOfExchangeRateChanges | -5.00K | -4.00K | -3.00K | |
| ChangesInCash | 6.68M | -1.11M | -3.17M | -35.40M |
| FinancingCashFlow | 7.35M | 11.34M | 16.15M | -2.18M |
| CashFlowFromContinuingFinancingActivities | 7.35M | 11.34M | 16.15M | -2.18M |
| NetOtherFinancingCharges | -1.63M | -5.00K | -191.00K | |
| NetPreferredStockIssuance | 0.00 | 15.00M | ||
| PreferredStockIssuance | 0.00 | 15.00M | ||
| NetCommonStockIssuance | 10.18M | 14.86M | 15.02M | 101.00K |
| CommonStockPayments | 0.00 | -6.00K | ||
| CommonStockIssuance | 10.18M | 14.86M | 15.02M | 107.00K |
| NetIssuancePaymentsOfDebt | -1.20M | -3.51M | -13.68M | -2.28M |
| NetShortTermDebtIssuance | -646.00K | -992.00K | -1.44M | -1.53M |
| ShortTermDebtPayments | -646.00K | -992.00K | -1.44M | -1.53M |
| NetLongTermDebtIssuance | -558.00K | -2.52M | -12.23M | -750.00K |
| LongTermDebtPayments | -558.00K | -2.52M | -12.23M | -750.00K |
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -4.87M | -3.04M | -2.40M | 311.00K |
| CashFlowFromContinuingInvestingActivities | -4.87M | -3.04M | -2.40M | 311.00K |
| NetInvestmentPurchaseAndSale | -3.85M | 9.60M | -2.12M | 833.00K |
| SaleOfInvestment | 2.00M | 15.30M | 19.18M | 26.89M |
| PurchaseOfInvestment | -5.86M | -5.70M | -21.30M | -26.06M |
| NetBusinessPurchaseAndSale | 0.00 | -12.36M | 0.00 | |
| PurchaseOfBusiness | 0.00 | -12.36M | 0.00 | |
| NetPPEPurchaseAndSale | -1.01M | -284.00K | -281.00K | -522.00K |
| PurchaseOfPPE | -1.01M | -284.00K | -281.00K | -522.00K |
| OperatingCashFlow | 4.20M | -9.41M | -16.93M | -33.53M |
| CashFlowFromContinuingOperatingActivities | 4.20M | -9.41M | -16.93M | -33.53M |
| ChangeInWorkingCapital | -1.53M | -7.24M | -2.13M | -4.84M |
| ChangeInOtherWorkingCapital | -46.00K | -3.81M | -3.83M | -2.03M |
| ChangeInOtherCurrentLiabilities | -1.45M | -1.47M | 1.11M | -1.82M |
| ChangeInOtherCurrentAssets | 2.72M | 1.82M | ||
| ChangeInPayablesAndAccruedExpense | -2.68M | 87.00K | 314.00K | -416.00K |
| ChangeInAccruedExpense | -1.03M | -376.00K | ||
| ChangeInPayable | -1.65M | 463.00K | 314.00K | -416.00K |
| ChangeInAccountPayable | -1.65M | 463.00K | 314.00K | -416.00K |
| ChangeInPrepaidAssets | 374.00K | 1.41M | 2.72M | |
| ChangeInInventory | -332.00K | 1.18M | -2.10M | -656.00K |
| ChangeInReceivables | 2.61M | -4.64M | -346.00K | -1.74M |
| ChangesInAccountReceivables | 2.61M | -4.64M | -346.00K | -1.74M |
| OtherNonCashItems | 2.39M | 3.12M | 2.38M | 369.00K |
| StockBasedCompensation | 1.29M | 932.00K | 315.00K | 943.00K |
| ProvisionandWriteOffofAssets | 425.00K | 1.10M | 610.00K | 146.00K |
| DepreciationAmortizationDepletion | 2.18M | 1.44M | 576.00K | 2.52M |
| DepreciationAndAmortization | 2.18M | 1.44M | 576.00K | 2.52M |
| Depreciation | 2.59M | 2.52M | ||
| OperatingGainsLosses | -74.00K | -320.00K | -7.00K | 10.00K |
| GainLossOnInvestmentSecurities | -74.00K | -321.00K | -4.00K | |
| NetForeignCurrencyExchangeGainLoss | -3.00K | 2.00K | ||
| NetIncomeFromContinuingOperations | -480.00K | -8.44M | -18.68M | -32.67M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for RMTI
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|